MedTrace Logo

Alternating Triamcinolone and Platelet-Rich Plasma Therapy for Oral Submucous Fibrosis

NCT07277998 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-12-11

No results posted yet for this study

Summary

Oral Submucous Fibrosis (OSF) is a chronic, progressive, potentially malignant disorder characterized by mucosal stiffness, trismus, and burning sensation. This interventional clinical trial evaluates the therapeutic effectiveness of alternating weekly intralesional Triamcinolone Acetonide (TA) and Platelet-Rich Plasma (PRP) injections compared to standard Triamcinolone therapy alone. The purpose is to determine whether sequential anti-inflammatory (TA) and regenerative (PRP) stimulation can produce superior clinical improvement in mouth opening, burning sensation, and mucosal flexibility compared to corticosteroid therapy alone.

Conditions

  • Oral Submucous Fibrosis

Interventions

BIOLOGICAL

Platelet-Rich Plasma (PRP) Injections

Autologous Platelet-rich plasma (PRP) injected intralesionally at standard volume for Oral submucous fibrosis (OSF) treatment, administered every alternate week.

DRUG

Triamcinolone Acetonide

Triamcinolone acetonide 10 mg/mL administered intralesionally once weekly.

Sponsors & Collaborators

  • Karachi Medical and Dental College

    lead OTHER

Principal Investigators

  • Sufyan Ahmed, BDS, FCPS · Karachi Medical and Dental College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-07-31
Completion
2026-09-30

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07277998 on ClinicalTrials.gov